- Home
- AGEN vs MSD Comparison
AGEN vs MSD Comparison
Compare AGEN & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- MSD
- Stock Information
- Founded
- AGEN 1994
- MSD 1993
- Country
- AGEN United States
- MSD United States
- Employees
- AGEN N/A
- MSD N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- MSD Trusts Except Educational Religious and Charitable
- Sector
- AGEN Health Care
- MSD Finance
- Exchange
- AGEN Nasdaq
- MSD Nasdaq
- Market Cap
- AGEN 126.8M
- MSD 146.8M
- IPO Year
- AGEN 2000
- MSD N/A
- Fundamental
- Price
- AGEN $4.29
- MSD $7.24
- Analyst Decision
- AGEN Buy
- MSD
- Analyst Count
- AGEN 2
- MSD 0
- Target Price
- AGEN $14.50
- MSD N/A
- AVG Volume (30 Days)
- AGEN 460.1K
- MSD 70.2K
- Earning Date
- AGEN 11-10-2025
- MSD 01-01-0001
- Dividend Yield
- AGEN N/A
- MSD 11.26%
- EPS Growth
- AGEN N/A
- MSD N/A
- EPS
- AGEN N/A
- MSD N/A
- Revenue
- AGEN $106,829,000.00
- MSD N/A
- Revenue This Year
- AGEN $60.49
- MSD N/A
- Revenue Next Year
- AGEN N/A
- MSD N/A
- P/E Ratio
- AGEN N/A
- MSD N/A
- Revenue Growth
- AGEN N/A
- MSD N/A
- 52 Week Low
- AGEN $1.38
- MSD $6.11
- 52 Week High
- AGEN $7.34
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- MSD 38.50
- Support Level
- AGEN $4.17
- MSD $7.22
- Resistance Level
- AGEN $4.60
- MSD $7.34
- Average True Range (ATR)
- AGEN 0.28
- MSD 0.07
- MACD
- AGEN 0.04
- MSD -0.00
- Stochastic Oscillator
- AGEN 61.32
- MSD 10.26
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.